A novel C. diff vaccine shows promise

Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…

AI Summary: Researchers at Vanderbilt have reported a novel experimental vaccine that prevents Clostridioides difficile infection and reduces recurrence in early studies, demonstrating strong protective immune responses. The work offers a much‑needed alternative to antibiotics and recurrent‑infection management, though larger clinical trials will be required to confirm safety, durability and real‑world impact.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Nasal-spray ‘universal’ vaccine protects mice from many respiratory threats / 3 months

FDA to review Moderna’s experimental flu vaccine after reversal / 3 months

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months

Gene‑editing trials explore one‑time fix for high cholesterol / 3 months

Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months

Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months

Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months